Using TIMER 2.0, MED19 was shown to be highly expressed for bladder urothelial carcinoma (BLCA), breast cancer (BRCA), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD) and other types in the TCGA project (Figure 1A). Here, MED19 is linked to breast carcinoma.